Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease
- PMID: 24548002
- DOI: 10.1111/jgh.12557
Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease
Abstract
Background and aim: Controlled attenuation parameter (CAP) has been suggested as a noninvasive method for detection and quantification of hepatic steatosis. We aim to study the diagnostic performance of CAP in nonalcoholic fatty liver disease (NAFLD) patients.
Methods: Transient elastography was performed in consecutive NAFLD patients undergoing liver biopsy and non-NAFLD controls. The accuracy of CAP for the detection and quantification of hepatic steatosis was assessed based on histological findings according to the Nonalcoholic Steatohepatitis Clinical Research Network Scoring System.
Results: Data for 101 NAFLD patients (mean age 50.3 ± 11.3 years old, 51.5% male) and 60 non-NAFLD controls were analyzed. CAP was associated with steatosis grade (odds ratio [OR] = 29.16, P < 0.001), body mass index (BMI; OR = 4.34, P < 0.001) and serum triglyceride (OR = 13.59, P = 0.037) on multivariate analysis. The median CAP for steatosis grades S0, S1, S2, and S3 were 184 dB/m, 305 dB/m, 320 dB/m, and 324 dB/m, respectively. The areas under receiver operating characteristics curves (AUROC) for estimation of steatosis grades ≥ S1, S2, and S3 were 0.97, 0.86, and 0.75, respectively. The optimal CAP cutoffs for estimation of steatosis grades ≥ S1, S2, and S3 were 263 dB/m, 281 dB/m, and 283 dB/m, respectively. Among non-obese patients, the AUROC for estimation of steatosis grades ≥ S1 and S2 were 0.99 and 0.99, respectively. Among obese patients, the AUROC for estimation of steatosis grades ≥ S1, S2, and S3 were 0.92, 0.64, and 0.58, respectively.
Conclusions: CAP is excellent for the detection of significant hepatic steatosis. However, its accuracy is impaired by an increased BMI, and it is less accurate to distinguish between the different grades of hepatic steatosis.
Keywords: controlled attenuation parameter; hepatic steatosis; nonalcoholic fatty liver disease; noninvasive assessment.
© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.
Similar articles
-
Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.Liver Int. 2012 Jul;32(6):911-8. doi: 10.1111/j.1478-3231.2012.02820.x. Liver Int. 2012. PMID: 22672642
-
Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.J Gastroenterol Hepatol. 2016 Apr;31(4):848-55. doi: 10.1111/jgh.13219. J Gastroenterol Hepatol. 2016. PMID: 26514665
-
Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography.Liver Int. 2012 Jul;32(6):902-10. doi: 10.1111/j.1478-3231.2012.02781.x. Epub 2012 Mar 21. Liver Int. 2012. PMID: 22435761
-
A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease.Eur J Clin Invest. 2021 Feb;51(2):e13446. doi: 10.1111/eci.13446. Epub 2020 Dec 9. Eur J Clin Invest. 2021. PMID: 33128454
-
Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis.BMC Gastroenterol. 2019 Apr 8;19(1):51. doi: 10.1186/s12876-019-0961-9. BMC Gastroenterol. 2019. PMID: 30961539 Free PMC article.
Cited by
-
Attenuation parameter and liver stiffness measurement using FibroTouch vs Fibroscan in patients with chronic liver disease.PLoS One. 2021 May 3;16(5):e0250300. doi: 10.1371/journal.pone.0250300. eCollection 2021. PLoS One. 2021. PMID: 33939744 Free PMC article.
-
Noninvasive Diagnosis of Hepatic Steatosis Using Fat Attenuation Parameter Measured by FibroTouch and a New Algorithm in CHB Patients.Hepat Mon. 2016 Jul 24;16(9):e40263. doi: 10.5812/hepatmon.40263. eCollection 2016 Sep. Hepat Mon. 2016. PMID: 27822268 Free PMC article.
-
Current status of imaging in nonalcoholic fatty liver disease.World J Hepatol. 2018 Aug 27;10(8):530-542. doi: 10.4254/wjh.v10.i8.530. World J Hepatol. 2018. PMID: 30190781 Free PMC article. Review.
-
Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.Dig Dis Sci. 2020 Feb;65(2):623-631. doi: 10.1007/s10620-019-5477-1. Epub 2019 Jan 25. Dig Dis Sci. 2020. PMID: 30684076
-
Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis.Int J Clin Exp Med. 2015 Oct 15;8(10):17654-63. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26770355 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous